Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer

Drugs

Volumn 71, Issue 7, 2011, Pages 841-852

  Salazar, Ramon ^a   Reidy Lagunes, Diane ^b   Yao, James ^c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dalotuzumab; Everolimus; Neuroendocrine tumours; Octreotide; Pasireotide; Sunitinib; Temsirolimus

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CIXUTUMUMAB; DALOTUZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TEPROTUMUMAB; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CARCINOID SYNDROME; DIARRHEA; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS;

EID: 79956160304     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585500-000000000-00000     Document Type: Article

References (69)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008; 100: 1282-1289.
3. Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15: 701-720.
4. Ö berg K, Jelic S, on behalf of the ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl. 4: iv150-153.
5. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (sstrs) in neuroendocrine tumors. Front Biosci 2008; 13: 822-840.
6. von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromagranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-4581. (Pubitemid 32103642)
7. Albanell J, Dalmases A, Rovira A, et al. mTOR signalling in human cancer. Clin Transl Oncol 2007; 9: 484-493.
8. Nilsson O, Wä ngberg B, Theodorsson E, et al. Presence of IGF-I in human midgut carcinoid tumours: an autocrine regulator of carcinoid tumour growth? Int J Cancer 1992; 51: 195-203.
9. Hö rsch D, Tielke S, Schrader J. Expression and activation of mTOR in neuroendocrine tumors: effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation, and signaling in neuroendocrine cell lines [abstract no. 10570]. J Clin Oncol 2007; 25 (18S): 582s.
10. Grozinsky-Glasberg S, Franchi G, TengM, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008; 87: 168-181. (Pubitemid 351563811)
11. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24: 28-47. (Pubitemid 36223278)
12. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996; 334: 246-254. (Pubitemid 26030676)
13. Ö berg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973. (Pubitemid 39004355)
14. Modlin IM, Pavel M, Kidd M, et al. Review articles: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
15. KurosakiM, Saeger W, Abe T, et al. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 2008; 30: 518-522. (Pubitemid 352008712)
16. Anthony LB, Martin W, Delbeke D, et al. Somatostatin receptor imaging: predictive and prognostic considerations. Digestion 1996; 57: 50-53. (Pubitemid 26183922)
17. Townsend A, Price T, Yeend S, et al. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol 2010; 44: 195-199.
18. Aparicio T, Ducreux M, Baudin E, et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Cancer 2001; 37: 1014-1019. (Pubitemid 32397687)
19. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated enteropancreatic endocrine carcinoma. Ann Oncol 2006; 17: 461-466. (Pubitemid 43329584)
20. Rinke A, Mü ller HH, Schade-Brittinger C, et al. Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
21. Kvols L, Wiedenmann B, Ö berg K, et al. Efficacy and safety results from a phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NET refractory or resistant to octreotide LAR [poster presentation C57]. Conference of the European Neuroendocrine Tumour Society; 2010 Mar 11-12; Berlin.
22. Novartis Pharmaceuticals. An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin [ClinicalTrials.gov identifier NCT00958841]. US National Institutes of Health, Clinical Trials.gov [online].Available fromURL: http://www.clinical trials.gov [Accessed 2009 Jul 21].
23. Novartis Pharmaceuticals. A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues [ClinicalTrials.gov identifier NCT00690430]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Jul 21].
24. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3: 302-310.
25. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989; 9: 889-892. (Pubitemid 19266323)
26. Schmid HA, Stumm M, McSheehy P, et al. Inhibitory effect of pasireotide in a rat pancreatic tumor model (CA20948) alone and in combination with everolimus (RAD001) [poster]. Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO).
27. Friedlander T, Weinberg V, Sharib J, et al. Effect of the somatostatin analog octreotide acetate on circulating IGF-1 and on PSA in patients with castration-resistant prostate cancer (CRPC): results of a phase II study [abstract no. 99 plus poster]. Genitourinary Cancers Symposium; 2010 Mar 5-7; San Francisco (CA).
28. Pokrajac A, Frystyk J, Flyvbjerg A, et al. Pituitaryindependent effect of octreotide on IGF1 generation. Eur J Endocrinol 2009; 160: 543-548.
29. ReidyDL, Hollywood E, Segal M, et al.A phase II clinical trial ofMK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs) [abstract no. 4163]. J Clin Oncol 2010; 28 Suppl.: 15s.
30. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 671-688. (Pubitemid 44151605)
31. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27 (13): 2278-2287.
32. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65: 889-893.
33. Samlowski WE, Vogelzang NJ. Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs 2007; 12: 605-618. (Pubitemid 350189126)
34. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AktmTOR pathway. J Clin Oncol 2010; 28: 245-255.
35. Ter-Minassian M, Wang Z, Asomaning K, et al. Association of a TSC2 SNP with sporadic neuroendocrine tumor risk [abstract no. 3050]. Proceedings of the Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO).
36. Moreno A, Akcakanat A, Munsell MF, et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15: 257-266. (Pubitemid 351449744)
37. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-0319. (Pubitemid 32803017)
38. Artime MC, Blackman S, Ebbinghaus S, et al. PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinicalmodels [abstract no. 3478]. Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21;Washington (DC).
39. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85: 54-60. (Pubitemid 46550026)
40. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95: 1148-1154. (Pubitemid 44660065)
41. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
42. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
43. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-0934.
44. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietin and VEGF. Oncogene 1999; 18: 5356-5362. (Pubitemid 29462372)
45. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
46. Inoue M, Hager JH, FerraraN, et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002; 1: 193-202. (Pubitemid 41039165)
47. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003; 34: 18-27. (Pubitemid 36160017)
48. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-1486. (Pubitemid 46595681)
49. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003; 16: 652-659. (Pubitemid 36871497)
50. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-952. (Pubitemid 46202314)
51. Yao VJ, Sennino B, Davis RB, et al. Combined anti- VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models [abstract]. Eur J Cancer 2006; 4 Suppl.: 27-28.
52. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35. (Pubitemid 46630490)
53. Kulke MH, Lenz HJ,Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
54. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
55. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008; 26: 1316-1323.
56. Yao JC, Phan AT, Fogelman D, et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker [abstract no. 4002]. J Clin Oncol 2010; 28 Suppl.: 15s.
57. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007; 13: 5232-5237. (Pubitemid 47510344)
58. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508. (Pubitemid 43259931)
59. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004; 136: 1297-1302. (Pubitemid 39647548)
60. Charland S, Boucher M-J, Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001; 142: 121-128. (Pubitemid 32183673)
61. Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010; 70: 666-674.
62. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
63. Pavel M, Hainsworth JD, Baudin E, et al. A randomized, double blind, placebo-controlled, multicenter phase III trial of everolimus 1 octreotide lar vs placebo 1 octreotide in patients with advanced neuroendocrine tumors (NET) (RADIANT-2) [abstract]. Ann Oncol 2010; 21: 4.
64. Sathyanarayanan S, Jha S, Klinghoffer R, et al. Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity [poster]. Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO).
65. Merck. A phase I study of ridaforolimus (MK8669) and MK0646 in patients with advanced cancer [ClinicalTrials. gov identifier NCT00730379]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Jul 21].
66. Hoffmann-La Roche. A multiple ascending dose study of the mTOR inhibitor (RAD001) in combination with R1507 in patients with advanced solid tumors [ClinicalTrials.gov identifier NCT00985374]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
67. M.D. Anderson Cancer Center. Phase I study of anti-IGF- 1R monoclonal antibody, IMC-A12, and mTOR inhibitor, everolimus, in advanced low to intermediate grade neuroendocrine carcinoma [ClinicalTrials.gov identifier NCT01204476]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2011 Feb 20].
68. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125-134.
69. Hobday TJ, Rubin J, Holen K, et al. MCO44h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. [abstract no. 4504] J Clin Oncol 2007; 25 Suppl. 18: 4504